GI Pancreatic - Metastatic

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

Localized

Adjuvant

NeoAdjuvant

IRB# 19211
A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

IRB# 17751
Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

IRB# 17094
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

IRB# 21790
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas

http://www.ohsu.edu/research/rda/so/knight.php

Cross-Disease Trials:

IRB# 19211
EAY131 (MATCH)

IRB# 20679
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

Key

[ ] Open for Enrollment
[ ] In Development
[ ] Enrollment on Hold